The U.S. Food and Drug Administration has granted approval to Eli Lilly's GLP-1 pill, Foundayo, representing a notable advancement for the Indianapolis-based pharmaceutical company as it enters the weight-loss medication sector.
Eli Lilly has announced that Foundayo, designed for once-daily consumption, will be accessible via its direct-to-consumer platform, LillyDirect, starting Monday. In addition, it will be available at various pharmacies and through telehealth services shortly thereafter. Patients with insurance may incur a cost of approximately $25 per month when utilizing a coupon, while those paying out-of-pocket can anticipate prices ranging from $149 to $349, contingent on the prescribed dosage.
This approval comes on the heels of an expedited review process, underscoring the drug's classification as a national priority. The launch follows shortly after Novo Nordisk received approval for its Wegovy pill. The competition within the GLP-1 category is intensifying, with analysts projecting that Foundayo could achieve $14.79 billion in sales by 2030, contrasting with $24.68 billion anticipated for Zepbound and $44.87 billion for Mounjaro.
Eli Lilly's CEO, Dave Ricks, underscored that although Foundayo may not match the efficacy of the company's injectable Zepbound, its oral format offers a level of convenience that may appeal to users who prefer pill-based medications over injections. Ricks highlighted that Foundayo’s small molecule structure allows for scalable production, which will facilitate its global distribution once regulatory approvals are secured in more than 40 countries.
Eli Lilly has devoted substantial resources to manufacturing capabilities, positioning itself to compete with other industry leaders such as Novo Nordisk. Analysts suggest that the cumulative sales of GLP-1 medications may draw new patients into obesity treatments, particularly given growing concerns over affordability. Furthermore, Foundayo's accessibility to seniors on Medicare, with reduced pricing set to commence this summer, reinforces its strategic positioning in the market.
As the landscape evolves, both Eli Lilly and Novo Nordisk are striving to establish their offerings as the preferred options for individuals seeking effective and manageable weight-loss solutions. Securing approvals and maintaining competitive pricing will be essential for both companies in the upcoming months.
Share this story